Form 4: Opus Genetics Executive Reports Routine Stock Transaction

Opus Genetics' Head of Financial Quality Assurance, Amy Zaremba, reported a disposition of 3,390 common shares to cover tax obligations related to an RSU vesting.

Summary

• Amy Zaremba, Head of Financial Quality Assurance at Opus Genetics, Inc., reported a transaction on January 18, 2026.
• The transaction involved the disposition of 3,390 shares of common stock.
• These shares were withheld by the Issuer to satisfy tax withholding obligations arising from the vesting and settlement of a restricted stock units (RSU) award.
• The disposition was not an open market sale of securities.
• The price per share for the disposition was $2.1.
• Following this transaction, Amy Zaremba beneficially owns 106,628 shares of common stock directly.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary transaction for tax withholding related to RSU vesting, which is a neutral event and does not indicate positive or negative sentiment about the company's performance or prospects.

Future Outlook

This filing is a historical report of an insider transaction and does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This is a routine insider transaction related to equity compensation and tax obligations, which is common across all industries for executives receiving restricted stock units. It does not provide specific insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, non-discretionary transaction for tax purposes, not a voluntary sale indicating a change in insider sentiment.
• Employees: Reflects standard equity compensation practices for executives, which can be a positive for employee retention and alignment of interests.

Key Dates

Keywords

Opus Genetics, IRD, Form 4, Insider Transaction, Restricted Stock Units, Tax Withholding, Equity Compensation